Winning Stock Forecast: Acadia, Protalix Bring Big Returns In The BioTech Space

ACAD Winning Stock Forecast

By Pöllö -commons.wikimedia.org

This week ACAD saw a 52.38% jump, being the 7 day forecast’s biggest earner, as the I Know First algorithm predicted. Before this week, ACAD’s shares have been under pressure from what turned out to be an inaccurate report from CNN. Acadia Pharmaceuticals is again bringing in impressive returns. The drug under fire was Nuplazid. The FDA only recently discarded these allegations to be untrue. Nuplazid made up $57.1 million in sales Q2 for ACAD, an 18% increase from the first quarter. Sales of the drug are increasing 87% year over year. The disproven safety concerns of Acadia’s drug quickly reflected a rise in stock.

(Yahoo Finance)

PLX Winning Stock Forecast

By Anja Martin, Labor Ralf Reski (http://en.wikipedia.org/wiki/Ralf_Reski) 

The second highest gainer of this week’s biotech forecast was PLX, rising 40.76%. Protalix BioTherapeutics quick incline in shares can be attributed to a recent announcement made by the company. After returning positive data in their research for the treatment of Fabry disease, this biotech company received attention. The plant-based biochemist company’s developments show their success in improving kidney function, caused by the disease. PLX also has an upcoming announcement on developments regarding lysosomal disease on October 5th. This may further effect the stock.

(Yahoo Finance)

 

Current I Know First subscribers received this bullish ACAD + PLX forecast on September 18th.

Algorithmic traders utilize these daily forecasts by the I Know First market prediction system as a tool to enhance portfolio performance, verify their own analysis and act on market opportunities faster. This forecast was sent to current I Know First subscribers.

How to interpret this diagram

Please note-for trading decisions use the most recent forecast. Get today’s forecast and Top stock picks.

 

About

ACADIA Pharmaceuticals Inc (NASDAQ:ACAD), a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. It is also developing pimavanserin as a treatment for dementia-related psychosis and as an adjunctive treatment for schizophrenia that are in phase III clinical trials; and pimavanserin as an adjunctive treatment for major depressive disorder. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Protalix BioTherapeutics, Inc (NASDAQ: PLX), a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company offers Elelyso, a plant cell expressed recombinant glucocerebrosidase enzyme for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in phase III clinical trials to treat Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that is in phase IIa clinical trials for the treatment of cystic fibrosis; and OPRX-106, an oral anti TNF product candidate, which is in Phase IIa clinical trial for the treatment of ulcerative colitis. Protalix BioTherapeutics, Inc. was founded in 1993 and is based in Karmiel, Israel.